Gossamer Bio Reacquires Seralutinib Rights, Cuts Debt by $115.9M; Q2 Net Income $16.9M
Gossamer Bio reported Q2 2026 financial results, including a net income of $16.9 million. The company reacquired worldwide development and commercial rights for seralutinib from Chiesi, consolidating global control and economics for its lead product. Stockholders also approved proposals related to a convertible note exchange, reducing debt by approximately $115.9 million, and authorized a reverse stock split to strengthen its capital structure. The company remains on track for a September 2026 NDA submission for seralutinib in PAH.
Key Highlights
- Reacquired worldwide development and commercial rights to seralutinib from Chiesi.
- Reduced aggregate principal debt by approximately $115.9 million through a convertible note exchange.
- Stockholders approved proposals for convertible note exchange and authorized a reverse stock split.
- NDA submission for seralutinib in PAH is on track for September 2026.
- Q2 2026 Net Income was $16.9 million, compared to a net loss of $38.3 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $57.0 million as of June 30, 2026.
- Q2 2026 R&D expenses decreased to $26.4 million from $41.6 million in Q2 2025.
- Q2 2026 Revenue from collaborators was $9.2 million, down from $11.5 million in Q2 2025.
Price Impact
More from GOSS
Gossamer Bio Q2 Operational Loss $(26.1)M; Going Concern Warning, 46% Workforce Cut
Gossamer Bio Reacquires Seralutinib Rights, Plans Sep 2026 FDA NDA
Gossamer Bio Boosts Authorized Shares to 4B; Approves Reverse Split